No Data
RBC: The first half of the year is expected to welcome positive catalysts. COMPASS Pathways (CMPS.US) and 12 other mid-small pharmaceutical stocks are worth a look.
RBC believes that some important catalysts for small and mid-cap Biotechnology companies in the first quarter of 2025 may have a significant impact on the Stocks it covers.
H.C. Wainwright Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $200
A Quick Look at Today's Ratings for Axsome Therapeutics(AXSM.US), With a Forecast Between $153 to $200
Axsome Therapeutics Price Target Maintained With a $200.00/Share by HC Wainwright & Co.
Axsome Therapeutics Full Year 2024 Earnings: EPS Misses Expectations
Analysts' Top Healthcare Picks: MiMedx Group (MDXG), Axsome Therapeutics (AXSM)
